Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Cash & Equivalents (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Cash & Equivalents for 5 consecutive years, with $57.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 48.56% to $57.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.1 million through Dec 2025, down 48.56% year-over-year, with the annual reading at $57.1 million for FY2025, 48.56% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $57.1 million at Werewolf Therapeutics, down from $65.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $183.2 million in Q2 2021, with the low at $57.1 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $125.3 million, with a median of $134.8 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 69.87% in 2022, then tumbled 48.56% in 2025.
  • Over 5 years, Cash & Equivalents stood at $157.5 million in 2021, then fell by 17.91% to $129.3 million in 2022, then increased by 3.89% to $134.3 million in 2023, then decreased by 17.38% to $111.0 million in 2024, then crashed by 48.56% to $57.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $57.1 million, $65.7 million, and $77.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.